Avesthagen, an integrated systems biology biotechnology company, has signed a memorandum of understanding with CosmosID, a US company, to diagnose and therapeutically manage tuberculosis treatment.
Both the companies are to pool their expertise to identify the TB strain and thereby support proper treatment. The collaboration is expected to result in a new method for developing diagnostic kits for rapid screening of patient samples.
According to Dr Villoo Morawala-Patell, Founder and CMD of Avesthagen, “Tuberculosis is a serious tropical disease and the efficacy of its treatment lies in accurate and rapid identification of the TB strains.”
“We at Avesthagen have been working on TB for some time and have developed a genomic data pool. In CosmosID, we have found a partner, developing rapid pathogen identification methods, MetaSeq Genomics, to facilitate more precise diagnostic screening of infectious disease in a single, rapid, and accurate test. The collaboration will help in improving healthcare in developing and less developed countries where it is needed the most,” she added.
Dr Rita Colwell, Founder and Chairman of CosmosID, said,”Our collaboration will provide significant benefits for TB patients worldwide and demonstrates a new paradigm for medical diagnostic screening of the infectious disease.”